AI reads CT scans to match kidney cancer patients with targeted drug
NCT ID NCT07332923
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at 500 kidney cancer patients to see if CT scans and machine learning can predict levels of a protein called HIF-2α. The goal is to better identify which patients might benefit from a targeted drug called Belzutifan, reducing unnecessary treatments and improving outcomes. The research is observational and does not test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
first hospital affiliated of Fujian medical university
Fuzhou, Fujian, 350005, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Drug cocktail aims to shrink kidney tumors before surgery and prevent return
- Smart bomb for kidney cancer: imaging and radiation combo targets tough tumors
- Personalized vaccine trains immune system to attack kidney cancer blood vessels